GSA Capital Partners’s Verve Therapeutics VERV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $437K | Sell |
38,912
-179,015
| -82% | -$2.01M | 0.03% | 1015 |
|
|
2025
Q1 | $996K | Buy |
217,927
+78,768
| +57% | +$360K | 0.09% | 347 |
|
|
2024
Q4 | $785K | Buy |
139,159
+103,057
| +285% | +$581K | 0.06% | 568 |
|
|
2024
Q3 | $175K | Sell |
36,102
-167,575
| -82% | -$812K | 0.01% | 1436 |
|
|
2024
Q2 | $994K | Buy |
+203,677
| New | +$994K | 0.07% | 505 |
|
|
2023
Q4 | – | Sell |
-56,895
| Closed | -$754K | – | 1958 |
|
|
2023
Q3 | $754K | Buy |
+56,895
| New | +$754K | 0.06% | 548 |
|
|
2023
Q2 | – | Sell |
-54,284
| Closed | -$783K | – | 1964 |
|
|
2023
Q1 | $783K | Buy |
+54,284
| New | +$783K | 0.08% | 453 |
|
|
2022
Q3 | – | Sell |
-25,544
| Closed | -$390K | – | 1887 |
|
|
2022
Q2 | $390K | Buy |
+25,544
| New | +$390K | 0.06% | 657 |
|